65:@0.890196:0.957873:0.907378:0.957873:0.907378:0.938882:0.890196:0.938882:0.008591:0.008591
3:@0.941813:0.310836:0.963291:0.310836:0.963291:0.263358:0.941813:0.263358:0.021478
PATIENT-DERIVED OVARIAN CANCER ORGANOIDS MIMIC CLINICAL RESPONSE AND:@0.411230:0.057372:0.882353:0.057372:0.882353:0.040253:0.411230:0.040253:0.007583:0.007097:0.006387:0.003511:0.006985:0.008759:0.005640:0.005155:0.008423:0.006985:0.008423:0.003511:0.007620:0.006985:0.008423:0.002988:0.008328:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.008442:0.008311:0.008292:0.007919:0.008759:0.008442:0.003511:0.008423:0.007807:0.002988:0.011112:0.003511:0.011112:0.003511:0.008255:0.002988:0.008255:0.006481:0.003511:0.008759:0.003511:0.008177:0.007919:0.006294:0.002988:0.008423:0.006871:0.007807:0.008050:0.008442:0.008759:0.007807:0.006985:0.002801:0.007919:0.008759:0.008423
EXHIBIT HETEROGENEOUS INTER- AND INTRAPATIENT DRUG RESPONSES:@0.468171:0.073247:0.882352:0.073247:0.882352:0.056128:0.468171:0.056128:0.006985:0.007527:0.008685:0.003511:0.008236:0.003511:0.006201:0.002988:0.008685:0.006985:0.006387:0.006985:0.008309:0.008442:0.008404:0.006985:0.008759:0.006985:0.008442:0.008367:0.007807:0.002988:0.003511:0.008759:0.006387:0.006985:0.008423:0.005155:0.002800:0.007919:0.008759:0.008423:0.002988:0.003511:0.008759:0.006387:0.008423:0.007919:0.007581:0.007097:0.006387:0.003511:0.006985:0.008759:0.006201:0.002988:0.008423:0.008367:0.008367:0.008404:0.002988:0.008423:0.006873:0.007807:0.008050:0.008442:0.008759:0.007807:0.006871:0.007807
months after the last primary treatment, and 6-month progression-free survival (PFS) :@0.147059:0.121273:0.886464:0.121273:0.886464:0.100900:0.147059:0.100900:0.017485:0.010843:0.011391:0.006620:0.011322:0.007670:0.005901:0.009085:0.006197:0.005969:0.009039:0.007807:0.005901:0.006620:0.011299:0.009039:0.005901:0.005433:0.009291:0.007512:0.006437:0.005898:0.011073:0.007807:0.005615:0.017574:0.009085:0.008400:0.009724:0.005901:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497:0.005901:0.009085:0.011598:0.011391:0.005898:0.010432:0.007533:0.017485:0.010843:0.011391:0.006620:0.011459:0.005901:0.011071:0.007444:0.011048:0.009861:0.007439:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.007533:0.006414:0.007442:0.009108:0.009039:0.005901:0.007510:0.011413:0.008400:0.009838:0.005547:0.009838:0.009405:0.005250:0.005901:0.006939:0.011664:0.011276:0.010112:0.006939:0.004109
did not correlate to PDO drug response. After 17 months 50% of patients with FIGO :@0.147059:0.141852:0.886482:0.141852:0.886482:0.121479:0.147059:0.121479:0.011391:0.005547:0.011391:0.006072:0.011596:0.010820:0.006437:0.006072:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006209:0.009039:0.006072:0.006209:0.011048:0.006072:0.011664:0.016504:0.016412:0.006072:0.011391:0.007964:0.011413:0.009861:0.006072:0.007442:0.009039:0.007510:0.011502:0.010845:0.011617:0.007875:0.008743:0.004497:0.006072:0.014929:0.006197:0.005969:0.009039:0.007807:0.006072:0.010432:0.010432:0.006072:0.017485:0.010843:0.011391:0.006620:0.011322:0.007670:0.006072:0.010432:0.010432:0.015043:0.006072:0.010843:0.006209:0.006072:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.006072:0.014723:0.005273:0.006620:0.011459:0.006072:0.011276:0.006825:0.015682:0.016412:0.004109
stage IV HGS OC are still alive (:@0.147059:0.162431:0.416301:0.162431:0.416301:0.142058:0.147059:0.142058:0.007510:0.006551:0.009199:0.009656:0.009039:0.004223:0.007259:0.015089:0.004223:0.016412:0.015682:0.010112:0.004223:0.016778:0.014678:0.004223:0.009085:0.007442:0.009039:0.004223:0.007512:0.006437:0.005750:0.005387:0.005250:0.004223:0.009405:0.005250:0.005547:0.009633:0.009039:0.004223:0.006939
Table S2:@0.416263:0.162431:0.489926:0.162431:0.489926:0.141298:0.416263:0.141298:0.011413:0.009679:0.011528:0.005935:0.009473:0.004132:0.010592:0.010911
); only one out of five patients (HGS-24) in our :@0.489917:0.162431:0.886508:0.162431:0.886508:0.142058:0.489917:0.142058:0.006939:0.004497:0.004223:0.010843:0.011870:0.005182:0.009724:0.004223:0.010843:0.011596:0.009039:0.004223:0.010820:0.011071:0.006437:0.004223:0.010843:0.006209:0.004223:0.005684:0.005615:0.009633:0.009039:0.004223:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004223:0.006939:0.016412:0.015682:0.010112:0.007533:0.010432:0.010432:0.006939:0.004223:0.005615:0.011756:0.004223:0.010818:0.011413:0.007807:0.004109
cohort lived shorter than 17 months, and this PDO exhibited the least responsiveness to :@0.147059:0.183009:0.886510:0.183009:0.886510:0.162636:0.147059:0.162636:0.008994:0.010934:0.011299:0.010843:0.007967:0.006437:0.004086:0.005250:0.005547:0.009633:0.009106:0.011391:0.004086:0.007556:0.011299:0.010843:0.007967:0.006209:0.009039:0.007807:0.004086:0.006620:0.011391:0.009087:0.011756:0.004086:0.010432:0.010432:0.004086:0.017485:0.010843:0.011393:0.006617:0.011324:0.007670:0.004497:0.004086:0.009085:0.011596:0.011391:0.004086:0.006617:0.011459:0.005615:0.007670:0.004086:0.011664:0.016504:0.016412:0.004086:0.009108:0.010089:0.011459:0.005547:0.010820:0.005273:0.006209:0.009108:0.011391:0.004086:0.006620:0.011299:0.009039:0.004086:0.005182:0.009288:0.009291:0.007512:0.006437:0.004086:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.004086:0.006209:0.011048:0.004109
carboplatin and paclitaxel combination treatment.:@0.147059:0.203588:0.568644:0.203588:0.568644:0.183215:0.147059:0.183215:0.009108:0.009085:0.007715:0.011254:0.010820:0.011162:0.005433:0.008811:0.006437:0.005615:0.011756:0.004109:0.009085:0.011596:0.011391:0.004109:0.011365:0.009291:0.008765:0.005250:0.005273:0.006551:0.009291:0.009884:0.008948:0.005250:0.004109:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.004109:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497
Figure 1: OC PDO drug response correlates with clinical drug response. (A) :@0.147059:0.580969:0.694430:0.580969:0.694430:0.563679:0.147059:0.563679:0.009488:0.005080:0.008797:0.009730:0.006761:0.007751:0.003110:0.008927:0.004445:0.003110:0.013877:0.012084:0.003108:0.010365:0.013727:0.013671:0.003110:0.009712:0.007284:0.009730:0.008591:0.003110:0.006761:0.007751:0.006574:0.009878:0.009265:0.009786:0.006740:0.007751:0.003110:0.007433:0.009265:0.006929:0.006761:0.007601:0.004856:0.007805:0.005622:0.007751:0.006574:0.003110:0.012233:0.005080:0.005939:0.009637:0.003110:0.007433:0.004781:0.005080:0.009955:0.005155:0.007693:0.008143:0.004781:0.003110:0.009712:0.007284:0.009730:0.008591:0.003110:0.006761:0.007751:0.006574:0.009880:0.009264:0.009786:0.006740:0.007508:0.004445:0.003110:0.006238:0.012345:0.006238:0.003287
Drug dose-response curves :@0.694253:0.580969:0.885705:0.580969:0.885705:0.564300:0.694253:0.564300:0.013111:0.006518:0.009338:0.008068:0.003175:0.009264:0.008965:0.006443:0.007396:0.006163:0.006089:0.007396:0.006145:0.009413:0.008871:0.009506:0.006443:0.007396:0.003175:0.007452:0.009338:0.006871:0.007883:0.007396:0.006275:0.003362
of OC PDOs for carboplatin and paclitaxel combination. Dose response curves are normalized to positive :@0.147059:0.595521:0.885769:0.595521:0.885769:0.578852:0.147059:0.578852:0.008871:0.005080:0.004127:0.013727:0.012009:0.004127:0.009544:0.013503:0.013298:0.006275:0.004127:0.004931:0.008871:0.006387:0.004127:0.007452:0.007433:0.006313:0.009207:0.008853:0.009133:0.004445:0.007209:0.005267:0.004594:0.009618:0.004127:0.007433:0.009488:0.009320:0.004127:0.009301:0.007601:0.007172:0.004296:0.004312:0.005360:0.007601:0.008087:0.007321:0.004296:0.004127:0.007359:0.008871:0.014233:0.008853:0.004594:0.009562:0.007209:0.005267:0.004537:0.008873:0.009618:0.003679:0.004127:0.013279:0.008965:0.006443:0.007396:0.004127:0.006089:0.007396:0.006145:0.009413:0.008871:0.009506:0.006443:0.007396:0.004127:0.007452:0.009338:0.006873:0.007881:0.007396:0.006275:0.004127:0.007433:0.006089:0.007396:0.004127:0.009488:0.008871:0.006387:0.014381:0.007695:0.004296:0.004594:0.007228:0.007452:0.009320:0.004127:0.005080:0.009039:0.004127:0.009413:0.008965:0.006219:0.004314:0.005267:0.004538:0.007881:0.007396:0.003362
(navitoclax, ABT-263) and negative controls (DMSO). Upper x-axis: carboplatin drug concentrations, lower :@0.147059:0.610073:0.885653:0.610073:0.885653:0.593405:0.147059:0.593405:0.005678:0.009562:0.007302:0.008050:0.004314:0.005080:0.009226:0.007172:0.004445:0.007601:0.008255:0.003679:0.002932:0.012214:0.010139:0.009656:0.006163:0.008535:0.008535:0.008535:0.005678:0.002932:0.007433:0.009488:0.009320:0.002932:0.009488:0.007396:0.008068:0.007209:0.005267:0.004538:0.007881:0.007396:0.002932:0.007359:0.008871:0.009320:0.005267:0.006089:0.008946:0.004296:0.006275:0.002932:0.005678:0.012681:0.016043:0.008274:0.013428:0.005678:0.003679:0.002932:0.012308:0.009039:0.009411:0.007396:0.006387:0.002932:0.008255:0.006163:0.007601:0.008255:0.004594:0.006275:0.003679:0.002932:0.007452:0.007433:0.006313:0.009207:0.008853:0.009133:0.004445:0.007209:0.005267:0.004594:0.009618:0.002932:0.009320:0.006518:0.009338:0.008068:0.002932:0.007359:0.008871:0.009488:0.007359:0.007396:0.009320:0.005267:0.006462:0.007209:0.005267:0.004538:0.008871:0.009506:0.006275:0.003679:0.002932:0.004240:0.008890:0.011878:0.007396:0.006387:0.003362
x-axis: paclitaxel drug concentrations. Each drug concentration was tested twice (technical replicate). Data :@0.147059:0.624625:0.885782:0.624625:0.885782:0.607957:0.147059:0.607957:0.008255:0.006163:0.007601:0.008255:0.004594:0.006275:0.003679:0.003978:0.009301:0.007601:0.007172:0.004296:0.004314:0.005360:0.007601:0.008087:0.007321:0.004296:0.003978:0.009320:0.006516:0.009338:0.008068:0.003978:0.007359:0.008869:0.009490:0.007359:0.007396:0.009320:0.005267:0.006462:0.007209:0.005267:0.004538:0.008871:0.009506:0.006275:0.003679:0.003978:0.010123:0.007601:0.007172:0.009376:0.003978:0.009320:0.006518:0.009338:0.008068:0.003978:0.007359:0.008871:0.009488:0.007359:0.007396:0.009320:0.005267:0.006462:0.007209:0.005267:0.004538:0.008871:0.009618:0.003978:0.012046:0.007601:0.006275:0.003978:0.005080:0.007396:0.006145:0.005080:0.007452:0.009320:0.003978:0.005267:0.012046:0.004538:0.007359:0.007396:0.003978:0.005678:0.005080:0.007450:0.007172:0.009376:0.009618:0.004538:0.007452:0.007695:0.004296:0.003978:0.006089:0.007471:0.009133:0.004296:0.004538:0.007452:0.007209:0.005080:0.007396:0.005678:0.003679:0.003978:0.013258:0.007209:0.005360:0.007601:0.003362
points and error bars represent the mean and standard deviation of one technical replicate. Non-linear :@0.147059:0.639177:0.885769:0.639177:0.885769:0.622509:0.147059:0.622509:0.009413:0.008871:0.004594:0.009320:0.005267:0.006275:0.005846:0.007433:0.009488:0.009320:0.005846:0.007396:0.006387:0.006089:0.008871:0.006387:0.005846:0.009095:0.007433:0.006238:0.006275:0.005846:0.006089:0.007471:0.009058:0.006089:0.007396:0.006443:0.007396:0.009320:0.005267:0.005846:0.005416:0.009245:0.007396:0.005846:0.014306:0.007601:0.007433:0.009618:0.005846:0.007433:0.009488:0.009320:0.005846:0.006145:0.005360:0.007433:0.009488:0.009469:0.007433:0.006089:0.009320:0.005846:0.009264:0.007639:0.008050:0.004744:0.007209:0.005267:0.004538:0.008871:0.009618:0.005846:0.008871:0.005080:0.005846:0.008871:0.009488:0.007396:0.005846:0.005080:0.007452:0.007172:0.009376:0.009618:0.004538:0.007452:0.007695:0.004296:0.005846:0.006089:0.007471:0.009133:0.004296:0.004538:0.007452:0.007207:0.005082:0.007153:0.003679:0.005846:0.012700:0.008871:0.009618:0.006163:0.004296:0.004594:0.009488:0.007601:0.007433:0.006387:0.003362
regression analysis: log(inhibitor) vs. response fit. Red=clinically resistant, blue=clinically sensitive. :@0.147059:0.653730:0.855231:0.653730:0.855231:0.637061:0.147059:0.637061:0.006089:0.007396:0.008068:0.006089:0.007396:0.006163:0.006219:0.004538:0.008871:0.009618:0.006705:0.007435:0.009562:0.007695:0.004240:0.007956:0.006219:0.004594:0.006275:0.003679:0.006705:0.004240:0.009039:0.008068:0.005678:0.004594:0.009710:0.009376:0.004538:0.008853:0.004314:0.005080:0.008871:0.006387:0.005678:0.006705:0.008050:0.006275:0.003679:0.006705:0.006089:0.007396:0.006145:0.009411:0.008873:0.009506:0.006443:0.007396:0.006705:0.004650:0.004370:0.005267:0.003679:0.006705:0.011206:0.007452:0.009320:0.009637:0.007172:0.004296:0.004594:0.009618:0.004537:0.007452:0.007695:0.004408:0.004240:0.007956:0.006705:0.006089:0.007396:0.006219:0.004594:0.006145:0.005360:0.007433:0.009320:0.005267:0.003679:0.006705:0.008927:0.004015:0.009282:0.007396:0.009637:0.007172:0.004296:0.004594:0.009618:0.004538:0.007452:0.007695:0.004408:0.004240:0.007956:0.006705:0.006443:0.007396:0.009506:0.006219:0.004314:0.005267:0.004538:0.007881:0.007153:0.003679:0.003362
(B):@0.858615:0.653730:0.882353:0.653730:0.882353:0.636439:0.858615:0.636439:0.006238:0.011262:0.006238
 :@0.882352:0.653730:0.885714:0.653730:0.885714:0.637061:0.882352:0.637061:0.003362
Overview of PDO drug response (area under the curve (AUC)) versus all clinical response measures, ordered :@0.147059:0.668282:0.885675:0.668282:0.885675:0.651613:0.147059:0.651613:0.013821:0.007881:0.007396:0.006873:0.008050:0.004538:0.007639:0.012046:0.002540:0.008871:0.005080:0.002540:0.009544:0.013503:0.013428:0.002540:0.009320:0.006518:0.009338:0.008068:0.002540:0.006089:0.007396:0.006145:0.009411:0.008871:0.009508:0.006442:0.007396:0.002540:0.005678:0.007433:0.006089:0.007601:0.007601:0.002540:0.009338:0.009490:0.009264:0.007396:0.006387:0.002540:0.005416:0.009245:0.007396:0.002540:0.007452:0.009338:0.006871:0.007883:0.007396:0.002540:0.005678:0.011056:0.013111:0.012009:0.005678:0.005678:0.002540:0.007883:0.007396:0.006236:0.006146:0.009338:0.006275:0.002540:0.007695:0.004408:0.004296:0.002540:0.007172:0.004296:0.004594:0.009618:0.004538:0.007450:0.007695:0.004296:0.002540:0.006089:0.007396:0.006145:0.009413:0.008871:0.009506:0.006443:0.007396:0.002540:0.014306:0.007601:0.007601:0.006145:0.009338:0.006089:0.007396:0.006275:0.003679:0.002540:0.008871:0.006089:0.009264:0.007396:0.006089:0.007452:0.009320:0.003362
from low responsive to high responsive based on AUC values. Histopathological tumor response: CRS1=no :@0.147059:0.682834:0.885640:0.682834:0.885640:0.666165:0.147059:0.666165:0.005248:0.006089:0.008871:0.014437:0.003194:0.004240:0.008890:0.012046:0.003194:0.006090:0.007396:0.006143:0.009413:0.008871:0.009508:0.006219:0.004538:0.007881:0.007396:0.003194:0.005080:0.009039:0.003194:0.009376:0.004594:0.008124:0.009376:0.003194:0.006089:0.007396:0.006145:0.009413:0.008871:0.009506:0.006219:0.004538:0.007881:0.007396:0.003194:0.009094:0.007601:0.006443:0.007452:0.009320:0.003194:0.008873:0.009618:0.003194:0.011056:0.013111:0.012009:0.003194:0.008050:0.007695:0.004015:0.009282:0.007396:0.006275:0.003679:0.003194:0.013484:0.004594:0.006145:0.005080:0.008853:0.009301:0.007209:0.005416:0.009245:0.008946:0.004240:0.009039:0.008068:0.004538:0.007452:0.007695:0.004296:0.003194:0.005043:0.009338:0.014306:0.008871:0.006387:0.003194:0.006089:0.007396:0.006146:0.009411:0.008871:0.009506:0.006443:0.007396:0.003679:0.003194:0.012009:0.010944:0.008274:0.008535:0.009637:0.009488:0.009039:0.003362
or minimal response vs CRS2=appreciable response; p=5.821e-05. Biochemical response: no normalization :@0.147059:0.697386:0.885780:0.697386:0.885780:0.680717:0.147059:0.680717:0.008871:0.006387:0.003250:0.014437:0.004594:0.009618:0.004594:0.014381:0.007695:0.004296:0.003250:0.006089:0.007396:0.006146:0.009411:0.008871:0.009506:0.006443:0.007396:0.003250:0.008050:0.006275:0.003250:0.012009:0.010944:0.008274:0.008535:0.009637:0.007209:0.009039:0.009058:0.006089:0.007452:0.007359:0.004742:0.007452:0.008927:0.004241:0.007396:0.003250:0.006089:0.007396:0.006145:0.009413:0.008871:0.009506:0.006443:0.007396:0.003679:0.003250:0.009226:0.009637:0.008535:0.003679:0.008535:0.008535:0.008535:0.007396:0.006163:0.008535:0.008535:0.003679:0.003240:0.010216:0.004538:0.009226:0.007172:0.009245:0.007396:0.014437:0.004538:0.007452:0.007695:0.004296:0.003250:0.006089:0.007396:0.006145:0.009413:0.008871:0.009506:0.006443:0.007396:0.003679:0.003250:0.009488:0.009039:0.003250:0.009488:0.008871:0.006387:0.014381:0.007695:0.004296:0.004594:0.007228:0.007211:0.005267:0.004540:0.008869:0.009618:0.003362
(<35 kU/L) of serum CA-125 during primary treatment vs normalization; p=0.0004. Radiological response: :@0.147059:0.711938:0.885694:0.711938:0.885694:0.695269:0.147059:0.695269:0.005678:0.009450:0.008535:0.008535:0.003231:0.008610:0.013111:0.005808:0.009506:0.005678:0.003231:0.008871:0.005080:0.003231:0.006443:0.007396:0.006518:0.009338:0.014437:0.003231:0.012009:0.011131:0.006163:0.008535:0.008535:0.008535:0.003231:0.009039:0.009338:0.006387:0.004594:0.009376:0.008068:0.003231:0.009058:0.006387:0.004594:0.014381:0.007433:0.006871:0.007956:0.003231:0.005267:0.006089:0.007601:0.007209:0.005267:0.014306:0.007396:0.009320:0.005267:0.003231:0.008050:0.006275:0.003231:0.009490:0.008871:0.006387:0.014381:0.007693:0.004296:0.004594:0.007228:0.007209:0.005267:0.004538:0.008871:0.009618:0.003679:0.003231:0.009226:0.009637:0.008535:0.003679:0.008535:0.008535:0.008535:0.008535:0.003679:0.003231:0.011374:0.007601:0.009320:0.004540:0.008946:0.004240:0.009039:0.008068:0.004538:0.007452:0.007695:0.004296:0.003231:0.006090:0.007396:0.006145:0.009411:0.008873:0.009504:0.006443:0.007396:0.003679:0.003362
stable disease (SD) vs partial response (PR) according to RECIST criteria; p=0.0092. See also Figure S1D-H. :@0.147059:0.726490:0.885688:0.726490:0.885688:0.709821:0.147059:0.709821:0.006145:0.005360:0.007452:0.008927:0.004240:0.007396:0.003287:0.009320:0.004594:0.006443:0.007601:0.007601:0.006442:0.007396:0.003287:0.005678:0.007994:0.013204:0.005678:0.003287:0.008050:0.006275:0.003287:0.009301:0.007433:0.006518:0.005267:0.004744:0.007695:0.004296:0.003287:0.006089:0.007396:0.006145:0.009413:0.008871:0.009506:0.006443:0.007396:0.003287:0.005678:0.009542:0.010944:0.005678:0.003287:0.007601:0.007359:0.007359:0.008871:0.006089:0.009320:0.004594:0.009376:0.008068:0.003287:0.005080:0.009039:0.003287:0.010944:0.009899:0.012009:0.005939:0.008068:0.010926:0.003287:0.007359:0.006387:0.004314:0.005080:0.007396:0.006387:0.004744:0.007601:0.003679:0.003287:0.009226:0.009637:0.008535:0.003679:0.008535:0.008535:0.008535:0.008535:0.003679:0.003287:0.008666:0.007452:0.007396:0.003287:0.007695:0.004296:0.006442:0.009039:0.003287:0.009320:0.004594:0.008068:0.009338:0.006089:0.007396:0.003287:0.008274:0.008535:0.013204:0.006163:0.013783:0.003679:0.003362
*Statistically significant difference between the clinically sensitive and resistant group according to Wilcoxon :@0.147059:0.741042:0.885655:0.741042:0.885655:0.724373:0.147059:0.724373:0.006686:0.008012:0.005360:0.007209:0.005267:0.004594:0.006145:0.005267:0.004538:0.007452:0.007693:0.004408:0.004240:0.007956:0.002708:0.006219:0.004594:0.008068:0.009618:0.004594:0.004650:0.004594:0.007452:0.007433:0.009320:0.005267:0.002708:0.009320:0.004594:0.004884:0.004734:0.007396:0.006087:0.007396:0.009490:0.007359:0.007396:0.002708:0.009207:0.007471:0.005267:0.011878:0.007452:0.007396:0.009618:0.002708:0.005414:0.009247:0.007396:0.002708:0.007172:0.004296:0.004594:0.009618:0.004538:0.007452:0.007695:0.004408:0.004240:0.007956:0.002708:0.006442:0.007396:0.009508:0.006219:0.004314:0.005267:0.004537:0.007881:0.007396:0.002708:0.007433:0.009490:0.009320:0.002708:0.006089:0.007396:0.006219:0.004594:0.006145:0.005360:0.007433:0.009320:0.005267:0.002708:0.008068:0.006089:0.008853:0.009058:0.009226:0.002708:0.007601:0.007359:0.007359:0.008871:0.006089:0.009320:0.004594:0.009376:0.008068:0.002708:0.005080:0.009039:0.002708:0.016323:0.004706:0.004240:0.007359:0.008853:0.008087:0.008871:0.009618:0.003362
signed-rank test corrected for multiple testing (p<0.01).:@0.147059:0.755594:0.527160:0.755594:0.527160:0.738925:0.147059:0.738925:0.006219:0.004594:0.008068:0.009488:0.007452:0.009320:0.006163:0.006462:0.007433:0.009712:0.008610:0.003362:0.005078:0.007396:0.006146:0.005267:0.003362:0.007359:0.008869:0.006387:0.006089:0.007452:0.007452:0.005080:0.007452:0.009320:0.003362:0.004931:0.008871:0.006387:0.003362:0.014138:0.009450:0.004015:0.005267:0.004314:0.009133:0.004240:0.007396:0.003362:0.005080:0.007396:0.006145:0.005267:0.004594:0.009376:0.008068:0.003362:0.005678:0.009226:0.009450:0.008535:0.003679:0.008535:0.008535:0.005678:0.003679
 :@0.147059:0.791805:0.153405:0.791805:0.153405:0.773993:0.147059:0.773993:0.006346
PDOs exhibit interpatient drug response heterogeneity which correlates partially :@0.147059:0.828562:0.886338:0.828562:0.886338:0.805402:0.147059:0.805402:0.010733:0.011231:0.011256:0.010409:0.003897:0.009363:0.010135:0.011579:0.004856:0.010982:0.004856:0.008365:0.003897:0.004856:0.011679:0.008616:0.009363:0.011231:0.010110:0.009463:0.008616:0.004856:0.009363:0.011679:0.008367:0.003897:0.011231:0.011156:0.011156:0.011206:0.003895:0.011231:0.009214:0.010409:0.010733:0.011256:0.011679:0.010409:0.009363:0.003897:0.011579:0.009363:0.008616:0.009363:0.011081:0.011256:0.011206:0.009363:0.011679:0.009363:0.004856:0.008616:0.010058:0.003648:0.015987:0.011579:0.004856:0.011007:0.011579:0.003897:0.011007:0.011256:0.011231:0.011231:0.009363:0.008691:0.009460:0.008616:0.009214:0.010409:0.003897:0.010110:0.010558:0.011081:0.008616:0.004856:0.010558:0.008691:0.006948:0.010060:0.003984
with their genetic makeup:@0.147059:0.847965:0.379120:0.847965:0.379120:0.824805:0.147059:0.824805:0.015987:0.004856:0.008616:0.011579:0.003984:0.008616:0.011579:0.009363:0.004856:0.011231:0.003984:0.011206:0.009363:0.011679:0.009363:0.008616:0.004856:0.011007:0.003984:0.014817:0.010558:0.010708:0.009363:0.011156:0.010733
Next, we investigated the response of all PDOs (N=36) to a broader range of drugs and :@0.147059:0.889888:0.886532:0.889888:0.886532:0.869515:0.147059:0.869515:0.015522:0.009108:0.010089:0.006437:0.004497:0.004931:0.014518:0.009039:0.004931:0.005615:0.011368:0.009633:0.009039:0.007510:0.006437:0.005615:0.009861:0.008811:0.006209:0.009108:0.011391:0.004931:0.006620:0.011299:0.009039:0.004931:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004931:0.010843:0.006209:0.004931:0.009405:0.005387:0.005250:0.004931:0.011664:0.016501:0.016255:0.007670:0.004931:0.006939:0.016230:0.011779:0.010432:0.010432:0.006939:0.004931:0.006209:0.011048:0.004931:0.009291:0.004931:0.010820:0.007442:0.011139:0.009291:0.011322:0.009039:0.007807:0.004931:0.007898:0.009085:0.011459:0.009656:0.009039:0.004931:0.010840:0.006209:0.004931:0.011391:0.007967:0.011413:0.009724:0.007670:0.004931:0.009085:0.011598:0.011391:0.004109
drug combinations (3-17 per PDO, on average 13; :@0.147059:0.910467:0.555569:0.910467:0.555569:0.890094:0.147059:0.890094:0.011391:0.007967:0.011413:0.009861:0.001995:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.001997:0.006939:0.010432:0.007533:0.010432:0.010432:0.001995:0.011505:0.009039:0.007807:0.001995:0.011664:0.016504:0.015385:0.004497:0.001995:0.010845:0.011756:0.001995:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.001997:0.010432:0.010432:0.004497:0.004109
Table S3:@0.553456:0.910467:0.624938:0.910467:0.624938:0.889334:0.553456:0.889334:0.011413:0.009679:0.011528:0.005935:0.009473:0.001952:0.010592:0.010911
), including chemotherapeutics :@0.624938:0.910467:0.886462:0.910467:0.886462:0.890094:0.624938:0.890094:0.006939:0.004497:0.001995:0.005615:0.011596:0.008765:0.004908:0.011345:0.011391:0.005615:0.011459:0.009861:0.001997:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011505:0.009131:0.011071:0.006437:0.005547:0.008994:0.007670:0.004109
ORGANOID:@0.314215:0.428462:0.381399:0.428462:0.381399:0.416800:0.314215:0.416800:0.009506:0.008841:0.009506:0.008841:0.008841:0.009506:0.003565:0.008579
RESPONSE:@0.315967:0.436807:0.380169:0.436807:0.380169:0.425146:0.315967:0.425146:0.008318:0.007664:0.007664:0.007664:0.008983:0.008318:0.007664:0.007926
SAMPLE:@0.235163:0.457792:0.286639:0.457792:0.286639:0.446131:0.235163:0.446131:0.008318:0.008971:0.010290:0.008318:0.007652:0.007926
AUC:@0.336403:0.457229:0.361618:0.457229:0.361618:0.445568:0.336403:0.445568:0.008318:0.008318:0.008579
Histopathological* Biochemical* Radiological* Progress Free:@0.404558:0.448606:0.763647:0.448606:0.763647:0.436945:0.404558:0.436945:0.008318:0.003042:0.006345:0.003695:0.006999:0.006999:0.006345:0.003695:0.006999:0.006999:0.003042:0.006999:0.006999:0.003042:0.006345:0.006345:0.003042:0.004622:0.010767:0.008971:0.003695:0.007652:0.006999:0.007652:0.006999:0.010956:0.003695:0.006999:0.006999:0.003695:0.004622:0.006332:0.008318:0.006345:0.006999:0.003042:0.006999:0.003042:0.006999:0.006999:0.003042:0.006345:0.006345:0.003042:0.004622:0.006426:0.008318:0.005014:0.007652:0.007652:0.005014:0.006999:0.006999:0.006999:0.003695:0.007652:0.005014:0.006999:0.006607
f:@0.562712:0.446291:0.567460:0.446291:0.567460:0.432298:0.562712:0.432298:0.004748
orem ipsum:@0.562712:0.458407:0.643533:0.458407:0.643533:0.444413:0.562712:0.444413:0.008712:0.005547:0.007928:0.012677:0.003964:0.003964:0.008712:0.007928:0.008712:0.012677
Chemotherapy:@0.414701:0.457797:0.489751:0.457797:0.489751:0.446599:0.414701:0.446599:0.008318:0.006345:0.006345:0.009637:0.006345:0.003042:0.006345:0.006345:0.003695:0.006345:0.006345:0.005941
Response Score:@0.405504:0.465706:0.498437:0.465706:0.498437:0.454507:0.405504:0.454507:0.008971:0.006999:0.006333:0.006999:0.006999:0.006999:0.006333:0.006999:0.003695:0.008318:0.006333:0.006999:0.004349:0.006607
Lorem ipsum:@0.611590:0.424618:0.680259:0.424618:0.680259:0.413420:0.611590:0.413420:0.006607:0.006607:0.003957:0.006607:0.009898:0.003303:0.002638:0.006607:0.005941:0.006607:0.009898
Lorem ipsum:@0.607051:0.427185:0.675720:0.427185:0.675720:0.415986:0.607051:0.415986:0.006607:0.006607:0.003957:0.006607:0.009898:0.003303:0.002638:0.006607:0.005941:0.006607:0.009898
Lorem ipsum:@0.586196:0.434244:0.654866:0.434244:0.654866:0.423045:0.586196:0.423045:0.006607:0.006607:0.003957:0.006607:0.009898:0.003303:0.002638:0.006607:0.005941:0.006607:0.009898
CA-125:@0.532995:0.457797:0.571970:0.457797:0.571970:0.446599:0.532995:0.446599:0.008318:0.007664:0.003695:0.006345:0.006345:0.006607
normalization:@0.513697:0.465706:0.590483:0.465706:0.590483:0.454507:0.513697:0.454507:0.007118:0.007118:0.004468:0.010409:0.007118:0.003149:0.003149:0.006452:0.007118:0.003814:0.003149:0.007118:0.006607
RECIST:@0.615587:0.457797:0.657854:0.457797:0.657854:0.446599:0.615587:0.446599:0.008318:0.007664:0.008318:0.003042:0.007664:0.007260
Survival:@0.696512:0.457791:0.745492:0.457791:0.745492:0.446130:0.696512:0.446130:0.008318:0.007652:0.005014:0.006999:0.003695:0.006999:0.006999:0.003303
(>6 months):@0.685675:0.465708:0.754511:0.465708:0.754511:0.454510:0.685675:0.454510:0.004468:0.007450:0.007118:0.003814:0.010409:0.007118:0.007118:0.003814:0.007118:0.006452:0.003957
Overall:@0.789384:0.448606:0.832031:0.448606:0.832031:0.436945:0.789384:0.436945:0.009637:0.006999:0.006999:0.005014:0.006999:0.003695:0.003303
Survival*:@0.786529:0.457791:0.839478:0.457791:0.839478:0.446130:0.786529:0.446130:0.008187:0.007522:0.004884:0.006868:0.003565:0.006868:0.006868:0.003565:0.004622
(>17 months):@0.778366:0.465708:0.844385:0.465708:0.844385:0.454510:0.778366:0.454510:0.003565:0.006547:0.006215:0.006215:0.002911:0.009506:0.006215:0.006215:0.002911:0.006215:0.005549:0.003957
HGS-24:@0.228974:0.478547:0.273201:0.478547:0.273201:0.467349:0.228974:0.467349:0.008841:0.009506:0.008187:0.004218:0.006868:0.006607
0.88:@0.336310:0.479834:0.360966:0.479834:0.360966:0.468636:0.336310:0.468636:0.007118:0.003814:0.007118:0.006607
CRS-1:@0.437514:0.478547:0.472116:0.478547:0.472116:0.467349:0.437514:0.467349:0.008318:0.008318:0.007664:0.003695:0.006607
NO:@0.545408:0.478547:0.562970:0.478547:0.562970:0.467349:0.545408:0.467349:0.008318:0.009245
SD:@0.628823:0.478547:0.645720:0.478547:0.645720:0.467349:0.628823:0.467349:0.008318:0.008579
YES:@0.709518:0.478547:0.734079:0.478547:0.734079:0.467349:0.709518:0.467349:0.008318:0.008318:0.007926
NO:@0.802000:0.478547:0.819563:0.478547:0.819563:0.467349:0.802000:0.467349:0.008318:0.009245
HGS-13.3:@0.228986:0.490099:0.283646:0.490099:0.283646:0.478901:0.228986:0.478901:0.008841:0.009506:0.008187:0.004218:0.006868:0.006868:0.003565:0.006607
0.75:@0.336322:0.491386:0.360978:0.491386:0.360978:0.480188:0.336322:0.480188:0.007118:0.003814:0.007118:0.006607
CRS-1:@0.437526:0.490099:0.472128:0.490099:0.472128:0.478901:0.437526:0.478901:0.008318:0.008318:0.007664:0.003695:0.006607
NO:@0.545419:0.490099:0.562982:0.490099:0.562982:0.478901:0.545419:0.478901:0.008318:0.009245
SD:@0.628835:0.490099:0.645732:0.490099:0.645732:0.478901:0.628835:0.478901:0.008318:0.008579
YES:@0.709530:0.490099:0.734091:0.490099:0.734091:0.478901:0.709530:0.478901:0.008318:0.008318:0.007926
YES:@0.799291:0.490099:0.823852:0.490099:0.823852:0.478901:0.799291:0.478901:0.008318:0.008318:0.007926
HGS-6:@0.228998:0.501651:0.266357:0.501651:0.266357:0.490453:0.228998:0.490453:0.008841:0.009506:0.008187:0.004218:0.006607
0.61:@0.336333:0.502938:0.360990:0.502938:0.360990:0.491740:0.336333:0.491740:0.007118:0.003814:0.007118:0.006607
CRS-1:@0.437537:0.501651:0.472139:0.501651:0.472139:0.490453:0.437537:0.490453:0.008318:0.008318:0.007664:0.003695:0.006607
NO:@0.545431:0.501651:0.562994:0.501651:0.562994:0.490453:0.545431:0.490453:0.008318:0.009245
PR:@0.628847:0.501651:0.645744:0.501651:0.645744:0.490453:0.628847:0.490453:0.008318:0.008579
NO:@0.712263:0.501651:0.729825:0.501651:0.729825:0.490453:0.712263:0.490453:0.008318:0.009245
YES:@0.799303:0.501651:0.823864:0.501651:0.823864:0.490453:0.799303:0.490453:0.008318:0.008318:0.007926
HGS-1:@0.229010:0.513203:0.266369:0.513203:0.266369:0.502004:0.229010:0.502004:0.008841:0.009506:0.008187:0.004218:0.006607
0.50:@0.336345:0.514490:0.361002:0.514490:0.361002:0.503292:0.336345:0.503292:0.007118:0.003814:0.007118:0.006607
CRS-1:@0.437549:0.513203:0.472152:0.513203:0.472152:0.502004:0.437549:0.502004:0.008318:0.008318:0.007664:0.003695:0.006607
NO:@0.545443:0.513203:0.563006:0.513203:0.563006:0.502004:0.545443:0.502004:0.008318:0.009245
SD:@0.628859:0.513203:0.645756:0.513203:0.645756:0.502004:0.628859:0.502004:0.008318:0.008579
NO:@0.712275:0.513203:0.729837:0.513203:0.729837:0.502004:0.712275:0.502004:0.008318:0.009245
YES:@0.799315:0.513203:0.823876:0.513203:0.823876:0.502004:0.799315:0.502004:0.008318:0.008318:0.007926
HGS-13.4:@0.229022:0.524755:0.283682:0.524755:0.283682:0.513556:0.229022:0.513556:0.008841:0.009506:0.008187:0.004218:0.006868:0.006868:0.003565:0.006607
0.48:@0.336357:0.526042:0.361014:0.526042:0.361014:0.514844:0.336357:0.514844:0.007118:0.003814:0.007118:0.006607
CRS-2:@0.437561:0.524755:0.472163:0.524755:0.472163:0.513556:0.437561:0.513556:0.008318:0.008318:0.007664:0.003695:0.006607
NO:@0.545455:0.524755:0.563018:0.524755:0.563018:0.513556:0.545455:0.513556:0.008318:0.009245
SD:@0.628871:0.524755:0.645768:0.524755:0.645768:0.513556:0.628871:0.513556:0.008318:0.008579
YES:@0.709566:0.524755:0.734127:0.524755:0.734127:0.513556:0.709566:0.513556:0.008318:0.008318:0.007926
YES:@0.799327:0.524755:0.823888:0.524755:0.823888:0.513556:0.799327:0.513556:0.008318:0.008318:0.007926
HGS-3.1:@0.229034:0.536307:0.276825:0.536307:0.276825:0.525108:0.229034:0.525108:0.008841:0.009506:0.008187:0.004218:0.006868:0.003565:0.006607
0.37:@0.336369:0.537594:0.361026:0.537594:0.361026:0.526395:0.336369:0.526395:0.007118:0.003814:0.007118:0.006607
CRS-2:@0.437573:0.536307:0.472175:0.536307:0.472175:0.525108:0.437573:0.525108:0.008318:0.008318:0.007664:0.003695:0.006607
YES:@0.542746:0.536307:0.567307:0.536307:0.567307:0.525108:0.542746:0.525108:0.008318:0.008318:0.007926
PR:@0.628883:0.536307:0.645780:0.536307:0.645780:0.525108:0.628883:0.525108:0.008318:0.008579
YES:@0.709577:0.536307:0.734139:0.536307:0.734139:0.525108:0.709577:0.525108:0.008318:0.008318:0.007926
YES:@0.799338:0.536307:0.823900:0.536307:0.823900:0.525108:0.799338:0.525108:0.008318:0.008318:0.007926
HGS-3.2:@0.228131:0.547858:0.275923:0.547858:0.275923:0.536660:0.228131:0.536660:0.008841:0.009506:0.008187:0.004218:0.006868:0.003565:0.006607
0.29:@0.337557:0.549146:0.362214:0.549146:0.362214:0.537947:0.337557:0.537947:0.007118:0.003814:0.007118:0.006607
CRS-2:@0.437573:0.547858:0.472175:0.547858:0.472175:0.536660:0.437573:0.536660:0.008318:0.008318:0.007664:0.003695:0.006607
YES:@0.542746:0.547858:0.567307:0.547858:0.567307:0.536660:0.542746:0.536660:0.008318:0.008318:0.007926
PR:@0.628883:0.547858:0.645780:0.547858:0.645780:0.536660:0.628883:0.536660:0.008318:0.008579
YES:@0.709577:0.547858:0.734139:0.547858:0.734139:0.536660:0.709577:0.536660:0.008318:0.008318:0.007926
YES:@0.799338:0.547858:0.823900:0.547858:0.823900:0.536660:0.799338:0.536660:0.008318:0.008318:0.007926
Lorem ipsum:@0.815021:0.604712:0.897092:0.604712:0.897092:0.591884:0.815021:0.591884:0.007986:0.007986:0.005085:0.007267:0.011620:0.003634:0.003634:0.007986:0.007267:0.007986:0.011620
CLINICAL RESPONSE:@0.574137:0.432313:0.694733:0.432313:0.694733:0.420652:0.574137:0.420652:0.008318:0.006999:0.003042:0.008318:0.003042:0.008318:0.008318:0.006999:0.003042:0.008318:0.007664:0.007664:0.007664:0.008983:0.008318:0.007664:0.007926
A:@0.201486:0.235292:0.210923:0.235292:0.210923:0.222464:0.201486:0.222464:0.009437
B:@0.201486:0.425778:0.210923:0.425778:0.210923:0.412950:0.201486:0.412950:0.009437
Figure 1. OC PDO drug response correlates with clinical drug response:@0.201538:0.209739:0.631464:0.209739:0.631464:0.196912:0.201538:0.196912:0.007803:0.003451:0.007803:0.007803:0.004902:0.007084:0.003451:0.007084:0.003451:0.003451:0.009986:0.009254:0.003451:0.008535:0.009254:0.009986:0.003451:0.007803:0.004902:0.007803:0.007803:0.003451:0.004902:0.007084:0.007084:0.007803:0.007803:0.007803:0.007084:0.007084:0.003451:0.007084:0.007803:0.004902:0.004902:0.007084:0.003451:0.007084:0.004170:0.007084:0.007084:0.003451:0.009986:0.003451:0.004170:0.007803:0.003451:0.007084:0.003451:0.003451:0.007803:0.003451:0.007084:0.007084:0.003451:0.003451:0.007803:0.004902:0.007803:0.007803:0.003451:0.004902:0.007084:0.007084:0.007803:0.007803:0.007803:0.007084:0.007267
-1:@0.336876:0.245226:0.347440:0.245226:0.347440:0.234027:0.336876:0.234027:0.003957:0.006607
0:@0.380034:0.245226:0.386640:0.245226:0.386640:0.234027:0.380034:0.234027:0.006607
1:@0.421159:0.245226:0.427766:0.245226:0.427766:0.234027:0.421159:0.234027:0.006607
2:@0.462285:0.245226:0.468892:0.245226:0.468892:0.234027:0.462285:0.234027:0.006607
DMSO:@0.268028:0.235172:0.303046:0.235172:0.303046:0.223973:0.268028:0.223973:0.008365:0.009684:0.007724:0.009245
[- ctrl]:@0.269490:0.244847:0.297699:0.244847:0.297699:0.233649:0.269490:0.233649:0.003090:0.003743:0.003090:0.005727:0.003090:0.003743:0.002424:0.003303
ABT-263:@0.483305:0.235172:0.528257:0.235172:0.528257:0.223973:0.483305:0.223973:0.007712:0.007712:0.006393:0.003743:0.006393:0.006393:0.006607
[+ ctrl]:@0.488997:0.244847:0.520189:0.244847:0.520189:0.233649:0.488997:0.233649:0.003090:0.006726:0.003090:0.005727:0.003090:0.003743:0.002424:0.003303
-2:@0.326278:0.376103:0.336841:0.376103:0.336841:0.364905:0.326278:0.364905:0.003957:0.006607
-1:@0.361367:0.376103:0.371931:0.376103:0.371931:0.364905:0.361367:0.364905:0.003957:0.006607
0:@0.398476:0.376103:0.405083:0.376103:0.405083:0.364905:0.398476:0.364905:0.006607
1:@0.433566:0.376103:0.440172:0.376103:0.440172:0.364905:0.433566:0.364905:0.006607
2 ABT-263:@0.468655:0.376103:0.528567:0.377138:0.528567:0.365940:0.468655:0.364905:0.006607:0.008353:0.007712:0.007712:0.006393:0.003743:0.006393:0.006393:0.373183
DMSO:@0.268291:0.377138:0.303309:0.377138:0.303309:0.365940:0.268291:0.365940:0.008365:0.009684:0.007724:0.009245
[- ctrl]:@0.269740:0.386814:0.297950:0.386814:0.297950:0.375615:0.269740:0.375615:0.003090:0.003743:0.003090:0.005727:0.003090:0.003743:0.002424:0.003303
[+ ctrl]:@0.489307:0.386814:0.520499:0.386814:0.520499:0.375615:0.489307:0.375615:0.003090:0.006726:0.003090:0.005727:0.003090:0.003743:0.002424:0.003303
0:@0.256184:0.354394:0.262791:0.354394:0.262791:0.343196:0.256184:0.343196:0.006607
50:@0.249423:0.314127:0.262636:0.314127:0.262636:0.302928:0.249423:0.302928:0.006607:0.006607
100:@0.242662:0.273859:0.262482:0.273859:0.262482:0.262661:0.242662:0.262661:0.006607:0.006607:0.006607
% organoids alive:@0.240968:0.343081:0.240968:0.273694:0.224499:0.273694:0.224499:0.343081:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.091354:0.006604
HGS-1:@0.575612:0.304158:0.611165:0.304158:0.611165:0.292960:0.575612:0.292960:0.008389:0.009055:0.007736:0.003767:0.006607
HGS-3.1:@0.575613:0.334139:0.620696:0.334139:0.620696:0.322940:0.575613:0.322940:0.008389:0.009055:0.007736:0.003767:0.006417:0.003113:0.006607
HGS-3.2:@0.575612:0.349129:0.620695:0.349129:0.620695:0.337931:0.575612:0.337931:0.008389:0.009055:0.007736:0.003767:0.006417:0.003113:0.006607
HGS-6:@0.575612:0.289169:0.611165:0.289169:0.611165:0.277970:0.575612:0.277970:0.008389:0.009055:0.007736:0.003767:0.006607
HGS-13.3:@0.575612:0.274179:0.627111:0.274179:0.627111:0.262980:0.575612:0.262980:0.008389:0.009055:0.007736:0.003767:0.006417:0.006417:0.003113:0.006607
HGS-13.4:@0.575613:0.319148:0.627112:0.319148:0.627112:0.307950:0.575613:0.307950:0.008389:0.009055:0.007736:0.003767:0.006417:0.006417:0.003113:0.006607
HGS-24:@0.575613:0.259189:0.617582:0.259189:0.617582:0.247990:0.575613:0.247990:0.008389:0.009055:0.007736:0.003767:0.006417:0.006607
Controls:@0.575612:0.364119:0.618520:0.364119:0.618520:0.352920:0.575612:0.352920:0.008389:0.006417:0.006417:0.003113:0.003767:0.006417:0.002448:0.005941
Paclitaxel :@0.348190:0.387244:0.404419:0.387244:0.404419:0.375583:0.348190:0.375583:0.007736:0.006417:0.006417:0.003113:0.003113:0.003767:0.006417:0.006417:0.006417:0.003113:0.003303
[Log µM] :@0.404229:0.386815:0.452674:0.386815:0.452674:0.375616:0.404229:0.375616:0.003113:0.006417:0.006417:0.006417:0.003113:0.006844:0.009708:0.003113:0.003303
Carboplatin :@0.341860:0.235347:0.409100:0.235347:0.409100:0.223686:0.341860:0.223686:0.008390:0.006417:0.004433:0.007071:0.007071:0.007071:0.003114:0.006417:0.003767:0.003114:0.007071:0.003304
[Log µM] :@0.408898:0.234918:0.457729:0.234918:0.457729:0.223719:0.408898:0.223719:0.003114:0.006417:0.006417:0.006417:0.003114:0.006845:0.009899:0.003304:0.003304